

Imugene Receives Approval from Thailand for Commencement of its Gastric Cancer Study

- **Research Ethics Committee from the Faculty of Medicine, Chiang Mei University of Thailand grants approval to start site activation procedures**
- **This follows the earlier Institutional Review Board approvals from Taipei Veterans General Hospital (Taiwan) and University of Hong Kong for HER-Vaxx Phase 1b/2 Study in Gastric Cancer.**

22 August 2016: Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, is pleased to announce that it has received the required approval from the Research Ethics Review Board from the Faculty of Medicine, Chiang Mai University of Thailand to start the process for site activation for the Phase 1b/2 study of its HER-Vaxx immuno-oncology therapy in gastric cancer.

Imugene's Chief Operating Officer, Leslie Chong states, "This approval from the Research Ethics Committee of Chiang Mei University of Thailand is spectacular! With this committee's approval, we can now commence the necessary steps towards activating this site for the start of patient enrolment for the re-entry of HER-Vaxx in our Phase 1b/2 study in HER2 positive gastric cancer! I am delighted with the efforts of my Imugene clinical development team in their perseverance and dedication to the successful and pending re-entry of HER-Vaxx into the clinic in 2016."

The proposed HER-Vaxx Phase 1b/2 study will be conducted in two parts. The initial Phase 1b will enrol up to 18 patients to be treated with HER-Vaxx in combination with chemotherapy to interrogate three dose levels. This first stage will provide safety data, immunogenicity data (a measure of how many of the HER2 cancer fighting antibodies are produced), evaluate the booster schedule and determine the optimal recommended Phase 2 dose (RP2D) to take into the Phase 2 study. The larger open label Phase 2 study will recruit around 68 patients randomised into two arms of either HER-Vaxx plus standard-of-care or standard-of-care alone.

The trial details are listed on the ClinicalTrial.gov website.

Identifier: NCT02795988

Link: <https://clinicaltrials.gov/show/NCT02795988>

About Imugene

Imugene (ASX: IMU) is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets.

HER-Vaxx is a cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. This unique immunotherapy, developed by leading scientists at the Medical University of Vienna in Austria, is a peptide vaccine constructed from several B cell epitopes of HER-2/neu. It has been shown in pre-clinical studies and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target. HER-Vaxx's successful Phase 1 study was in patients with breast cancer and the next stage of development will be a Phase 1b/2 study in patients with gastric cancer initiating in 2016.

In January 2016 Imugene announced a new partnership with the Medical University of Vienna to discover and develop mimotope-based immunotherapies against validated and new oncology targets. This

partnership has the potential to create game-changing B Cell peptide vaccines that would replace or augment conventional monoclonal antibody therapies.

For further information, please visit www.imugene.com.

Sign up to follow @TeamImugene on Twitter at <http://www.twitter.com/TeamImugene>.

To follow Imugene on Facebook visit www.facebook.com/imugene.

For further information please contact:

Imugene:

Leslie Chong, Chief Operating Officer

Tel: +61 458 040 433 (Australia), [leslie.chong\[at\]imugene.com](mailto:leslie.chong[at]imugene.com)